Leap Therapeutics

May 13, 2024

•

Mar 31, 2024

Leap Therapeutics Q1 2024 Earnings Report

Leap Therapeutics reported financial results for the first quarter ended March 31, 2024.

Key Takeaways

Leap Therapeutics reported a net loss of $13.8 million for the first quarter of 2024. The company's cash and cash equivalents totaled $54.9 million at the end of the quarter, exclusive of the $37.2 million net proceeds from a private placement completed in April 2024. A recent $40 million financing extends the cash runway into the second quarter of 2026.

Net Loss was $13.8 million for the first quarter 2024, compared to $41.9 million for the same period in 2023.

Research and development expenses were $11.3 million for the first quarter 2024, compared to $38.9 million for the same period in 2023.

General and administrative expenses were $3.5 million for the first quarter 2024, compared to $3.8 million for the same period in 2022.

Cash and cash equivalents totaled $54.9 million at March 31, 2024, exclusive of the $37.2 million net proceeds of the private placement completed in April 2024.